This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
5 Must-Buy Stocks Amid Exaggerated Economic Slowdown
by Nalak Das
The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Concert Pharma Initiates Early-Stage Schizophrenia Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a huge amount of debt.
Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run
by Sweta Killa
Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overhyped toxic stocks are usually susceptible to external shocks and burdened with huge amount of debt.
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
by Zacks Equity Research
Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica
4 Toxic Stocks to Discard or Sell Short for Solid Gains
by Zacks Equity Research
Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
Merck Gets Priority Review for Keytruda in Third-Line SCLC
by Zacks Equity Research
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
by Zacks Equity Research
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Incyte (INCY) Q4 Earnings Lag Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -6.98% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica
by Zacks Equity Research
Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.